Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy

European Urology

Volumn 64, Issue 3, 2013, Pages 465-471

  Lotan, Yair ^a   Bagrodia, Aditya ^a   Passoni, Niccolo ^b   Rachakonda, Varun ^a   Kapur, Payal ^a   Arriaga, Yull ^a   Bolenz, Christian ^c   Margulis, Vitaly ^a   Raj, Ganesh V ^a   Sagalowsky, Arthur I ^a   Shariat, Shahrokh F ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Bladder cancer; Cystectomy; Molecular markers

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MONOCLONAL ANTIBODY KI 67; PACLITAXEL; PROTEIN P21; PROTEIN P27; PROTEIN P53; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PERIOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

BLADDER CANCER; CYSTECTOMY; MOLECULAR MARKERS;

AGED; CARCINOMA; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84881150674     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.043     Document Type: Article

References (26)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. Y. Lotan, R.S. Svatek, and A.I. Sagalowsky Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis Cancer 107 2006 982 990
3. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium J Urol 176 2006 2414 2422 discussion 2422
4. Y. Lotan, A. Gupta, and S.F. Shariat Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy J Clin Oncol 23 2005 6533 6539
5. J.P. Stein, G. Lieskovsky, and R. Cote Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients J Clin Oncol 19 2001 666 675
6. P.I. Karakiewicz, S.F. Shariat, and G.S. Palapattu Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder J Urol 176 2006 1354 1361 discussion 1361-2
7. B.H. Bochner, M.W. Kattan, and K.C. Vora Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer J Clin Oncol 24 2006 3967 3972
8. C. Bolenz, and Y. Lotan Molecular biomarkers for urothelial carcinoma of the bladder: Challenges in clinical use Nat Clin Pract Urol 5 2008 676 685
9. K. Bensalah, F. Montorsi, and S.F. Shariat Challenges of cancer biomarker profiling Eur Urol 52 2007 1601 1609
10. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis Hum Pathol 37 2006 1568 1576
11. S.F. Shariat, P.I. Karakiewicz, and R. Ashfaq Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 112 2007 315 325
12. S.F. Shariat, H. Tokunaga, and J. Zhou p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer J Clin Oncol 22 2004 1014 1024
13. V. Margulis, S.F. Shariat, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease Clin Cancer Res 12 2006 7369 7373
14. V. Margulis, Y. Lotan, and P.I. Karakiewicz Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer J Natl Cancer Inst 101 2009 114 119
15. S.F. Shariat, T.F. Chromecki, and E.K. Cha Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers J Urol 187 2012 457 462
16. S.F. Shariat, Y. Lotan, and P.I. Karakiewicz P53 predictive value for pT1-2 N0 disease at radical cystectomy J Urol 182 2009 907 913
17. S.F. Shariat, P.I. Karakiewicz, and R. Ashfaq Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy Cancer 112 2008 315 325
18. J.I. Epstein, M.B. Amin, V.R. Reuter, and F.K. Mostofi The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee Am J Surg Pathol 22 1998 1435 1448
19. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387
20. S.F. Shariat, C. Bolenz, and P.I. Karakiewicz P53 expression in patients with advanced urothelial cancer of the urinary bladder BJU Int 105 2009 489 495
21. S. Hernandez, E. Lopez-Knowles, and J. Lloreta FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis Clin Cancer Res 11 2005 5444 5450
22. E. Lopez-Knowles, S. Hernandez, M. Kogevinas EPICURO Study Investigators The p53 pathway and outcome among patients with T1G3 bladder tumors Clin Cancer Res 12 2006 6029 6036
23. G. Dalbagni, D.J. Parekh, L. Ben-Porat, M. Potenzoni, H.W. Herr, and V.E. Reuter Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder BJU Int 99 2007 281 285
24. W.M. Stadler, S.P. Lerner, and S. Groshen Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status J Clin Oncol 29 2011 3443 3449
25. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859 866
26. S.F. Shariat, A.R. Zlotta, R. Ashfaq, A.I. Sagalowsky, and Y. Lotan Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness Mod Pathol 20 2007 445 459